1296201-72-3

Upstream product

• 800402-12-4 2-chloro-4-amino-5-iodopyridine 
• 1066-54-2 trimethylsilylacetylene 
• 14432-12-3 4-Amino-2-chloropyridine 

Downstream Products

• 1296203-13-8 C₁₆H₁₄ClN₃O₂ 
• 800401-54-1 6-chloro-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid 
• 1000341-67-2 C₈H₅ClN₂O₂ 
• 74976-31-1 6-chloro-1H-pyrrolo[3,2-c]pyridine 

Relevant academic research and scientific papers

COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS

The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

BICYCLIC HETEROARYLS AS KINASE INHIBITORS

The invention is directed to heteroaryl compounds useful as inhibitors of various kinase enzymes. In various embodiments, the invention provides a heteroaryl compound having inhibitory bioactivity with respect to a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Flt kinase, an Aurora kinase, or a Src kinase, or any combination thereof. Compounds of the invention include bicyclic heteroaryl compounds of formula (I), which can contain a bridging nitrogen atom at a ring junction. The invention further provides methods of synthesis of compounds of the invention, pharmaceutical compositions, pharmaceutical combinations, and methods of treatment of malconditions using compounds of the invention.